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Background: In a randomized phase III study, trametinib prolonged progression-free survival and improved overall sur-
vival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma.
Patients and methods: Patients’ quality of life (QOL) was assessed at baseline and follow-up visits using the European
Organisation for Research and Treatment of Cancer Core QOL questionnaire.
Results: In the primary efﬁcacy population (BRAF V600E+, no brain metastases) from baseline toweeks 6 and 12, patients’
global health status scores worsened by 4–5 points with chemotherapy but improved by 2–3 points with trametinib. Rapid
and substantive reductions in QOL functionality (e.g. role functioning, 8–11 points at weeks 6 and 12) and symptom exacer-
bation (e.g. fatigue, 4–8 points; nausea and vomiting, 5 points, both at weeks 6 and 12) were observed in chemotherapy-
treated patients. In contrast, trametinib-treated patients reported small improvements or slight worsening from baseline at
week 12, depending on the functional dimension and symptom. The mean symptom-scale scores for chemotherapy-
treated patients increased from baseline (symptoms worsened) for seven of eight symptoms at week 6 (except insomnia)
and six of eight symptoms at week 12 (except dyspnea and insomnia). In contrast, at weeks 6 and 12, the mean symptom-
scale scores for trametinib decreased from baseline (symptoms improved) for pain (11–12 points), insomnia (10–12 points),
and appetite loss (1–5 points), whereas those for diarrhea worsened (15–16 points). Mixed-model repeated-measures ana-
lyses showed signiﬁcant (P < 0.05) and/or clinically meaningful improvements (small to moderate) from baseline in favor of
trametinib for global health; physical, role, and social functioning; fatigue; pain; insomnia; nausea and vomiting; constipation;
dyspnea; and appetite at weeks 6 and/or 12. QOL results for the intent-to-treat population were consistent.
Conclusions: This ﬁrst QOL assessment for a MEK inhibitor in metastatic melanoma demonstrated that trametinib was
associated with less functional impairment, smaller declines in health status, and less exacerbation of symptoms versus
chemotherapy.
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introduction
Activating mutations in BRAF, a constituent of the mitogen-
activated protein kinase (MAPK) signal transduction pathway,
are found in ∼50% of patients with advanced melanoma [1, 2].
The two most common BRAF mutations, V600E and V600K,
account for 95% of all BRAF mutations in melanoma. BRAF
activates MAPK/extracellular signal-regulated kinase kinase 1
(MEK1) and MEK2—which in turn activate downstream
MAPKs—and regulates tumor cell proliferation and survival in
many cancers, including melanoma [3].
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Until recently, only two agents had been approved for the treat-
ment of metastatic melanoma in the United States: dacarbazine
(DTIC) and interleukin‐2. Ipilimumab, a monoclonal antibody
targeting cytotoxic T-lymphocyte-associated antigen 4, and
vemurafenib, a selective BRAF inhibitor (BRAFi), were approved
in the United States and Europe in 2011/2012 to treat metastatic
melanoma. Dabrafenib, another selective BRAFi, and trametinib,
a highly selective allosteric inhibitor of MEK1 and MEK2 (MEKi),
were both approved recently in the United States (May 2013) for
unresectable or metastatic melanoma with BRAF V600 mutation.
In the pivotal METRIC study, trametinib decreased the risk of
progression or death by 55% versus chemotherapy in patients
with BRAF V600E or V600K mutation-positive metastatic mel-
anoma (intent-to treat [ITT] population; progression-free sur-
vival [PFS] of 4.8 versus 1.5 months; hazard ratio [HR] = 0.45;
95% conﬁdence interval [CI] 0.33–0.63; P < 0.0001) [4]. At 6
months, the rate of overall survival (OS) was 81% in the trameti-
nib group and 67% in the chemotherapy group despite crossover
(HR = 0.54; 95% CI, 0.32–0.92; P = 0.01). The primary efﬁcacy
analysis was restricted to patients with the BRAF V600E muta-
tion who did not have brain metastases at baseline (PFS of 4.8
versus 1.4 months; HR = 0.44; 95% CI 0.31–0.64; P < 0.001 and
OS HR = 0.53; 95% CI 0.30–0.94; P = 0.0181).
In addition to the clinical beneﬁts of any new treatment
option, another important goal is to preserve, and when pos-
sible, improve patients’ quality of life (QOL). Patient-perceived
QOL captures clinical beneﬁt and the impact of adverse events
in a single assessment. The objective of these analyses was to
evaluate the impact of the recently approved MEKi, trametinib,
on patients’ QOL versus chemotherapy. Patients in the analysis
reported here had been enrolled in the METRIC phase III trial
[4] and had BRAF V600E mutation-positive metastatic melan-
oma with no history of brain metastases. There were no a priori
hypotheses and no adjustments for multiple testing; all results
should be considered exploratory.
methods
study design and treatment regimen
METRIC (MEK114267; NCT01245062) is a randomized, two-arm, open-
label, international phase III study to evaluate the efﬁcacy and safety of
single-agent trametinib versus chemotherapy (DTIC or paclitaxel) [4].
Brieﬂy, patients with histologically conﬁrmed cutaneous advanced or meta-
static melanoma (stage IIIC or IV), with a BRAF V600E/K mutation-positive
tumor sample were randomized 2:1 to receive either trametinib 2 mg once
daily or chemotherapy. QOL was a secondary end point. Treatment contin-
ued until disease progression, death, or withdrawal from the study. Patients
on chemotherapy could cross over to receive trametinib after disease pro-
gression that had been conﬁrmed by an independent review. The primary
efﬁcacy population was patients with advanced/metastatic BRAF V600E mu-
tation-positive melanoma without a history of prior brain metastases. Of the
322 patients enrolled in the study, 273 patients (trametinib, n = 178; chemo-
therapy, n = 95) were included in the primary efﬁcacy population and are
presented herein. QOL results for the ITT population were consistent and
hence are not reported here.
QOL assessments
The European Organisation for Research and Treatment of Cancer QOL
Questionnaire (EORTC QLQ-C30) [5, 6] was used to evaluate QOL in this
study. The EORTC QLQ-C30 is a self-reported, 30-item generic instrument
for use in cancer patients across tumor types that include overall health/
global QOL, ﬁve functional scales, and nine symptom scales or single-item
questions. For global health status and the functional scales, a higher score
reﬂects better global health or functioning. Conversely, for symptom scales
or single items, higher scores indicate greater symptom severity. QOL assess-
ments were carried out at baseline (before any study drug was administered);
at weeks 6, 12, 21, 30, and every 12 weeks thereafter during treatment; on
progression; and 6 weeks after progression was ﬁrst determined. Data at
baseline, weeks 6 and 12, and on progression with chemotherapy are pre-
sented because of lower sample size/limited data availability after week 12.
statistical analysis
QOL data from the primary efﬁcacy population collected until the data cut-
off used for analyses of the primary end point were included. Analyses were
carried out for the randomized phase and for patients who crossed over to
trametinib on progression with chemotherapy. Baseline scores (deﬁned as
QOL assessment before ﬁrst dose) were reported with standard descriptive
statistics. For the crossover phase analysis, the assessment at disease progres-
sion while on chemotherapy was used as the baseline score. Changes in score
from baseline at each assessment were summarized for global health and for
each functional and symptom scale or single item. Analysis of covariance—
adjusted for baseline score using mixed-model repeated measures with time,
treatment, and treatment by time interaction as ﬁxed effects—was carried
out to assess differences between arms for global health and all functional
and symptom dimension scores. Time was treated as the repeated variable
within patients. Unstructured covariance matrices were used for these ana-
lyses.
results
randomized phase
baseline characteristics and QOL completion rates. Treatment
groups were well balanced, although more patients in the
trametinib group had M1c disease (characterized by metastasis to
sites beyond skin, lymph node, and lung or to any site with an
elevated lactate dehydrogenase level) and ≥3 sites of disease, as
reported previously [4]. At baseline, 92 and 87% of patients in the
trametinib and chemotherapy arms, respectively, completed QOL
assessments. The majority of patients (77%) in the trametinib arm
either completed all required QOL assessments or missed <3 post-
baseline assessments; the corresponding percentage was 62% for
patients in the chemotherapy arm (Supplementary Table S1,
available at Annals of Oncology online). At baseline, patients in
both arms reported comparable levels of mean functional and
symptom-related QOL with no difference between arms
exceeding 6 points (Table 1). Baseline scores here were
comparable with EORTC QLQ-C30 reference values from an
international sample of patients with stage III/IV malignant
melanoma [7].
impact on global health and functional QOL. Global health and
most functionality dimensions (Figure 1) worsened from
baseline for chemotherapy patients at weeks 6 and 12. For
trametinib patients, at weeks 6 and 12, global health and
physical and emotional functioning improved, but role and
cognitive functioning slightly worsened. In addition, global
health status scores worsened from baseline by 4–5 points for
chemotherapy patients but improved by 2–3 points for
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trametinib patients. Rapid and substantive reductions in QOL
functionality (e.g. role functioning = 8–11 points at weeks 6 and
12) were observed in chemotherapy-treated patients, consistent
with the faster progression observed within this group. In
contrast, trametinib-treated patients reported either small
decreases or improvements from baseline at week 12, depending
upon the functional dimension. Emotional functioning
improved most at week 6 (5 points) and week 12 (6 points). At
progression, large decreases (≥10 points) in global health and
physical, role, and social functional dimensions of QOL were
observed for chemotherapy versus trametinib.
Statistical differences for global health and functional
dimensions between arms were assessed using mixed-model
repeated-measures analysis (Table 2). A 5- and 6-point signiﬁcant
improvement (P < 0.05) from baseline in favor of trametinib was
observed for physical functioning at weeks 6 and 12, respectively
(Table 2). These mean changes in score can be considered ‘small’
clinically meaningful improvements [8]. Similarly a 7-point sign-
iﬁcant improvement in role functioning at week 6 (P = 0.043) and
a 10-point signiﬁcant improvement in social functioning at week
12 (P = 0.032) were observed in favor of trametinib, both consid-
ered ‘small’ clinically meaningful improvements [8].
impact on symptoms. At weeks 6 and 12, the mean symptom
scale scores for trametinib had decreased from baseline
(symptoms improved) for pain (11–12 points), insomnia (10–12
points), and appetite loss (1–5 points), whereas those for
diarrhea worsened (15–16 points) (Figure 2).
In contrast, the mean scores for chemotherapy-treated patients
increased from baseline (symptoms worsened) for seven of eight
symptoms at week 6 (except insomnia) and six of eight symptoms
at week 12 (except dyspnea and insomnia). At progression, all
symptoms (except diarrhea) worsened to a much greater degree
for chemotherapy- versus trametinib-treated patients. Fatigue,
Table 1. Summary of EORTC QLQ-C30 functionality and
symptom dimensions of QOL at baseline (primary efﬁcacy
population)—randomized phase
QOL dimension Trametinib
(n = 178)
Chemotherapy
(n = 95)
n Mean SD n Mean SD
Global health status/QOL 175 63.3 21.6 88 68.7 20.9
Physical functioning 173 81.2 20.1 86 82.8 18.9
Role functioning 172 73.1 30.5 87 74.3 28.2
Emotional functioning 174 72.3 23.6 87 76.5 20.8
Cognitive functioning 175 88.3 17.4 89 90.6 17.2
Social functioning 175 75.5 29.0 89 78.3 25.4
Fatigue 172 32.6 26.6 89 28.8 24.8
Nausea and vomiting 175 10.2 18.7 89 8.6 16.7
Pain 173 28.8 30.0 88 28.6 26.0
Dyspnea 174 20.1 30.0 89 15.0 21.9
Insomnia 175 30.3 31.0 88 24.6 27.5
Appetite loss 174 19.5 29.8 89 16.1 26.2
Constipation 175 11.1 21.9 89 12.4 22.7
Diarrhea 175 7.6 16.9 89 6.4 14.1
EORTC QLQ-C30, European Organisation for Research and
Treatment of Cancer Core Quality of Life Questionnaire; QOL,
quality of life; SD, standard deviation.
Values are rounded to one decimal place.
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nausea and vomiting, and dyspnea symptoms worsened most
upon progression for chemotherapy-treated patients. Pain, in-
somnia, constipation, dyspnea, and nausea and vomiting scores
were lower than baseline (symptoms improved) upon progression
for trametinib-treated patients.
Signiﬁcant differences for symptom dimensions between
arms were also assessed using mixed-model repeated-measures
analysis (Table 3). The mean pain scores signiﬁcantly improved
from baseline by 11 and 15 points in favor of trametinib at
weeks 6 and 12, respectively (‘moderate’ clinically meaningful
improvements). A 9-point signiﬁcant improvement in dyspnea
(P = 0.04) at week 6 and an 8-point signiﬁcant improvement in
appetite at week 12 (P = 0.038) were observed in favor of trame-
tinib (‘small’ clinically meaningful improvements). However,
diarrhea scores signiﬁcantly worsened (‘moderate’ clinical
change) from baseline by 12 and 11 points for trametinib at
weeks 6 and 12, respectively.
crossover phase
Patients receiving chemotherapy (n = 51) who crossed over to
trametinib on progression experienced moderate-to-large
clinically meaningful improvements in global health status and
functional dimension scores relative to their progression visit
scores. This suggested immediate beneﬁt after receiving trameti-
nib for 6–12 weeks; greatest improvements were observed for
role functioning (19 points), global health (14 points), and phys-
ical functioning (14 points) at week 6. Large improvements were
also observed for six of eight symptoms following 6 weeks of
treatment with trametinib, especially for pain (22 points), in-
somnia (15 points), and fatigue (15 points). In contrast, scores
for diarrhea worsened by 11 and 15 points and scores for consti-
pation worsened by 2 and 11 points, at weeks 6 and 12, respect-
ively (data not shown).
discussion
Health-related QOL is an important consideration for patients
with advanced or metastatic melanoma. Although treatments can
slow disease progression, thereby forestalling the effects of the
disease on QOL, side-effects of treatment can adversely affect
QOL. It is therefore vital to understand the impact of treatments
on patients’ overall QOL.
Table 2. Summary of mixed-model repeated-measures analysis for change from baseline in global health and functional dimension scores in
randomized phase
Domain Change from
baseline to
Treatment group n available
for QOL
Adjusted
mean
SEM Difference
(trametinib versus
chemotherapy)
Global health Week 6 Trametinib 144 2.3 1.3 4.0
Chemotherapy 57 −1.7 2.2
Week 12 Trametinib 104 1.2 1.7 5.7
Chemotherapy 32 −4.6 3.0
Cognitive functioning Week 6 Trametinib 145 −3.4 1.1 −3.8
Chemotherapy 58 0.3 1.8
Week 12 Trametinib 104 −2.6 1.2 −2.7
Chemotherapy 32 0.1 2.2
Emotional functioning Week 6 Trametinib 142 4.4 1.3 4.0
Chemotherapy 56 0.4 2.1
Week 12 Trametinib 101 5.6 1.5 3.8
Chemotherapy 31 1.8 2.6
Physical functioning Week 6 Trametinib 141 0.6 1.1 5.2a
Chemotherapy 56 −4.6 1.8
Week 12 Trametinib 104 −0.9 1.3 6.2a
Chemotherapy 30 −7.1 2.4
Role functioning Week 6 Trametinib 143 −0.5 1.8 7.0a
Chemotherapy 56 −7.4 2.9
Week 12 Trametinib 104 −4.0 2.4 8.9
Chemotherapy 31 −12.9 4.3
Social functioning Week 6 Trametinib 144 −2.4 1.8 −0.6
Chemotherapy 58 −1.8 2.9
Week 12 Trametinib 104 0.7 2.2 9.5a
Chemotherapy 32 −8.8 3.8
Trametinib, n = 178; chemotherapy, n = 95.
Values have been rounded to one decimal place.
QOL, quality of life; SEM, standard error of the mean.
aP < 0.05.
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In the METRIC study, trametinib-treated patients experi-
enced greater functional and symptomatic beneﬁts than chemo-
therapy patients. These results suggest a fairly quick and
substantive decrease in QOL functionality and exacerbation of
symptoms across assessments for patients on chemotherapy,
which were consistent with the faster progression observed for
chemotherapy patients. Overall decrease in functionality and
worsening of symptoms were greatest at disease progression for
chemotherapy patients, whereas trametinib patients reported
slight drops, slight improvements, or limited change in QOL
from baseline, depending on the functional dimension and
symptom. It is important to note that this study was not
powered for QOL. Signiﬁcant and/or clinically meaningful
improvements (small to moderate) [8] from baseline in favor of
trametinib were observed for global health; physical, role, and
social functioning; fatigue; pain; insomnia; nausea and vomiting;
constipation; dyspnea; and appetite at weeks 6 and/or 12.
Additionally, chemotherapy patients who crossed over to trame-
tinib on progression experienced large improvements in their
global health status, functionality dimensions, and most symp-
toms (except diarrhea and constipation) within 6 weeks of tra-
metinib treatment. However, this may have been due to these
patients having a positive attitude toward a new treatment.
Approximately one-third of melanoma patients have clinical-
ly signiﬁcant levels of distress, particularly around the time of
diagnosis and immediately after treatment [9, 10]. In the
current study, baseline values for emotional functioning were
among the lowest in global health and the ﬁve functional QOL
dimensions for both treatment arms, providing further evidence
that patients with newly diagnosed advanced or metastatic mel-
anoma have poor emotional state of mind. Additionally, trame-
tinib-treated patients reported the greatest impact on emotional
functioning at weeks 6 and 12 with a 5- to 6-point improvement
in scores relative to baseline.
There is limited information available on the QOL impact of
newer treatments for melanoma. Two studies have reported the
QOL impact of ipilimumab. In a study by Kotapati et al. [11],
patients were randomized to DTIC plus ipilimumab or DTIC
alone for 12 weeks, followed by 12 weeks of DTIC only. Changes
in score were considered as ‘no change’ (0–5 points), ‘a little’
(5–10 points), ‘moderate’ (10–20 points), and ‘very much’ (>20
points). At week 12, unadjusted mean changes from baseline in
both treatment groups were ‘no change’ to ‘moderate’ for all
QOL domains including symptom scores. Both groups experi-
enced a small decline in average global health status scores
(DTIC + placebo, −6.5; ipilimumab + DTIC, −10.0). In a
double-blind, three-arm study [12], patients with previously
treated advanced unresectable stage III or IV melanoma were
randomized 3:1:1 to ipilimumab + gp100, gp100 alone, or ipili-
mumab alone. For all study arms, the mean changes in score
from baseline to week 12 for global health (ipilimumab + gp100,
−7; ipilimumab, −9; gp100, −10), the ﬁve functional dimen-
sions (e.g. role functioning: ipilimumab + gp100, −9; ipilimu-
mab −11; gp100, −14), and all symptom scales (e.g. fatigue:
ipilimumab + gp100, +11; ipilimumab, +13; gp100, +15) sug-
gested functional impairment and symptom exacerbation.
The impact of dabrafenib (BRAFi) on QOL has been evalu-
ated versus DTIC in patients with BRAF V600E mutation-posi-
tive metastatic melanoma [13]. All functionality dimensions,
except role, worsened from baseline for DTIC at weeks 6 and 12.
For dabrafenib, all functionality scores remained close to base-
line or improved at week 6; however, by week 12, physical, role,
and cognitive functioning scores worsened by 1–3 points. A
clinically meaningful improvement in emotional function with
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dabrafenib compared with DTIC was observed at weeks 6 (11
points) and 12 (15 points). The mean change in symptom
dimensions represented improvements from baseline (except
fatigue) with dabrafenib, particularly for appetite loss, insomnia,
nausea and vomiting, and pain. Symptom dimensions worsened
or did not change from baseline for all symptoms (except pain
at week 6) with DTIC, the greatest exacerbations being for
fatigue, nausea and vomiting, appetite loss, and dyspnea.
The following limitations of this study should be considered
when interpreting the results. Patients participating in clinical
studies may be more motivated and optimistic and therefore
more likely to report beneﬁt and endure more treatment-related
toxicity. This was an open-label study; therefore, any expectations
about the potential effects of treatment may have biased the
responses to the EORTC QLQ-C30 questionnaire. Furthermore,
although the questionnaire is a widely used, reliable, and valid in-
strument for evaluating QOL in cancer [6, 14–17], the QOL
aspects were not speciﬁc to melanoma. Finally, all patients had an
ECOG performance status of 0 or 1 with a median age of 55
years, hence a relatively younger and healthier patient cohort, po-
tentially making it difﬁcult to demonstrate QOL improvement.
Preservation of QOL would be the desirable outcome.
This ﬁrst report of QOL assessment with an MEKi in meta-
static melanoma demonstrated that trametinib conferred a sign-
iﬁcant PFS and OS beneﬁt versus chemotherapy and that
trametinib-treated patients reported a better global health and
functional status and less exacerbation of symptoms. With
several targeted and immunotherapies being evaluated as
Table 3. Summary of mixed-model repeated-measures analysis for change from baseline in symptom dimension scores in randomized phase
Domain Change from
baseline to
Treatment
group
n available
for QOL
Adjusted
mean
SEM Difference (trametinib
versus chemotherapy)
Fatigue Week 6 Trametinib 140 1.4 1.8 −5.0
Chemotherapy 58 6.4 2.8
Week 12 Trametinib 102 4.4 2.0 −1.7
Chemotherapy 31 6.1 3.4
Nausea and
vomiting
Week 6 Trametinib 143 0.2 1.2 −4.5a
Chemotherapy 58 4.8 1.9
Week 12 Trametinib 105 2.8 1.5 −4.0
Chemotherapy 32 6.8 2.7
Pain Week 6 Trametinib 143 −11.4 1.7 −10.5a
Chemotherapy 57 −0.9 2.7
Week 12 Trametinib 103 −9.5 2.2 −14.8a
Chemotherapy 31 5.3 4.0
Dyspnea Week 6 Trametinib 144 −2.5 1.7 −9.3a
Chemotherapy 58 6.8 2.7
Week 12 Trametinib 104 3.4 2.1 2.9
Chemotherapy 32 0.6 3.7
Insomnia Week 6 Trametinib 144 −9.3 2.0 −6.6
Chemotherapy 57 −2.7 3.2
Week 12 Trametinib 105 −10.3 2.3 −9.1
Chemotherapy 32 −1.2 4.2
Appetite loss Week 6 Trametinib 143 −1.0 1.8 −5.2
Chemotherapy 58 4.3 2.9
Week 12 Trametinib 105 −3.0 2.0 −8.3a
Chemotherapy 32 5.4 3.4
Constipation Week 6 Trametinib 144 4.1 1.7 2.6
Chemotherapy 58 1.5 2.7
Week 12 Trametinib 104 3.8 1.9 −5.1
Chemotherapy 32 9.0 3.4
Diarrhea Week 6 Trametinib 145 15.4 1.9 12.1a
Chemotherapy 58 3.3 3.0
Week 12 Trametinib 104 16.5 2.1 11.5a
Chemotherapy 32 5.0 3.7
Trametinib, n = 178; chemotherapy, n = 95.
Values have been rounded to one decimal place.
CI, conﬁdence interval; QOL, quality of life; SE, standard error of the mean.
aP < 0.05.
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combinations or in sequence for the treatment of melanoma
QOL assessment will be of importance when assessing the clin-
ical beneﬁt of such treatments.
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